サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1605916

標的タンパク質分解市場、規模、シェア、動向、産業分析レポート：タイプ別、治療領域別、投与経路別、地域別 - 市場予測 2025年～2034年

Targeted Protein Degradation Market Size, Share, Trends, Industry Analysis Report: By Type, Therapeutic Area, Route of Administration, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
標的タンパク質分解市場、規模、シェア、動向、産業分析レポート：タイプ別、治療領域別、投与経路別、地域別 - 市場予測 2025年～2034年
出版日: 2024年11月01日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の標的タンパク質分解市場規模は2034年までに35億4,791万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

標的タンパク質分解（TPD）市場は、精密医療の進歩とバイオテクノロジーへの投資の増加により、著しい成長を遂げています。主な推進力は、これまで「治療不可能」だったタンパク質を標的とするTPDの可能性であり、がんや神経変性疾患などの複雑な疾患に対する新たな治療の道を開くものです。

製薬会社が学術機関やハイテク企業と共同で新規分解剤を開発することで、この市場開拓の機会は予測期間中に増加すると予想されます。個別化医療に向けた新たな傾向や低分子治療薬への注目の高まりも、市場の需要を後押ししています。全体として、研究活動や臨床試験の増加に伴い、TPD市場は急速な拡大が見込まれています。

標的タンパク質分解市場レポートハイライト

タイプ別では、タンパク質分解標的キメラ分子（PROTACs）分野が市場を独占しており、幅広いタンパク質を分解できることから広く採用されています。デグロニミドは、低分子治療薬の進歩に牽引され、急速な成長が見込まれています。

治療分野別では、がん治療が標的タンパク質の分解に大きく依存していることから、がん疾患分野が最大のシェアを占めています。神経疾患分野は、アルツハイマー病などの神経変性疾患に関する調査の増加に伴い、急成長が予測されています。

投与経路別では、静脈内投与が市場を独占しています。静脈内投与は、特に直接かつ制御された送達が必要な治療に用いられます。

北米は強力な研究開発活動と医薬品への投資によりTPD市場をリードしています。アジア太平洋地域は、ヘルスケア支出の増加、バイオテクノロジー分野の成長、革新的な治療法への注目の高まりにより、最も急速に成長している地域です。

同市場の主要企業には、Arvinas社、Kymera Therapeutics社、Nurix Therapeutics社などがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の標的タンパク質分解市場の洞察

  • 市場スナップショット
  • 標的タンパク質分解市場力学
    • 促進要因と機会
      • 腫瘍学アプリケーションの拡大
      • 神経疾患治療の増加
    • 抑制要因と課題
      • 医薬品開発と臨床検証の複雑さ
  • PESTEL分析
  • 標的タンパク質分解市場のアプリケーション動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の標的タンパク質分解市場：タイプ別

  • 主な調査結果
  • イントロダクション
  • デグロニミド
  • 免疫調節薬（IMiD）
  • タンパク質分解標的キメラ分子（PROTAC）
  • 突発性網膜変性症候群（SARD）
  • 選択的エストロゲン受容体分解薬（SERD）
  • その他

第6章 世界の標的タンパク質分解市場：治療領域別

  • 主な調査結果
  • イントロダクション
  • 炎症性疾患
  • 神経疾患
  • 腫瘍性疾患
  • 呼吸器疾患
  • その他

第7章 世界の標的タンパク質分解市場：投与経路別

  • 主な調査結果
  • イントロダクション
  • オーラル
  • 静脈内
  • その他

第8章 世界の標的タンパク質分解市場：地域別

  • 主な調査結果
  • イントロダクション
    • 標的タンパク質分解市場評価：地域別、2020～2034年
  • 北米
    • 北米：タイプ別、2020～2034年
    • 北米：治療領域別、2020～2034年
    • 北米：投与経路別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：タイプ別、2020～2034年
    • 欧州：治療領域別、2020～2034年
    • 欧州：投与経路別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：タイプ別、2020～2034年
    • アジア太平洋地域：治療領域別、2020～2034年
    • アジア太平洋地域：投与経路別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：タイプ別、2020～2034年
    • 中東・アフリカ：治療領域別、2020～2034年
    • 中東・アフリカ：投与経路別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：タイプ別、2020～2034年
    • ラテンアメリカ：治療領域別、2020～2034年
    • ラテンアメリカ：投与経路別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Arvinas
  • Kymera Therapeutics
  • Nurix Therapeutics
  • C4 Therapeutics
  • Foghorn Therapeutics
  • Zymeworks
  • Bristol-Myers Squibb
  • Pfizer
  • AbbVie
  • Molteni Farmaceutici
図表

List of Tables:

  • Table 1 Global Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 2 Global Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 3 Global Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 4 North America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 5 North America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 6 North America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 7 US: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 8 US: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 9 US: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 10 Canada: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 11 Canada: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 12 Canada: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 13 Europe: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 14 Europe: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 15 Europe: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 16 UK: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 17 UK: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 18 UK: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 19 France: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 20 France: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 21 France: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 22 Germany: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 23 Germany: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 24 Germany: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 25 Italy: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 26 Italy: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 27 Italy: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 28 Spain: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 29 Spain: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 30 Spain: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 31 Netherlands: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 32 Netherlands: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 33 Netherlands: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 34 Russia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 35 Russia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 36 Russia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 37 Rest of Europe: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 38 Rest of Europe: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 39 Rest of Europe: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 40 Asia Pacific: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 41 Asia Pacific: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 42 Asia Pacific: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 43 China: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 44 China: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 45 China: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 46 India: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 47 India: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 48 India: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 49 Malaysia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 50 Malaysia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 51 Malaysia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 52 Japan: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 53 Japan: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 54 Japan: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 55 Indonesia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 56 Indonesia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 57 Indonesia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 58 South Korea: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 59 South Korea: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 60 South Korea: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 61 Australia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 62 Australia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 63 Australia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 64 Rest of Asia Pacific: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 65 Rest of Asia Pacific: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 66 Rest of Asia Pacific: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 67 Middle East & Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 68 Middle East & Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 69 Middle East & Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 70 Saudi Arabia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 71 Saudi Arabia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 72 Saudi Arabia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 73 UAE: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 74 UAE: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 75 UAE: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 76 Israel: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 77 Israel: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 78 Israel: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 79 South Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 80 South Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 81 South Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 82 Rest of Middle East & Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 83 Rest of Middle East & Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 84 Rest of Middle East & Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 85 Latin America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 86 Latin America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 87 Latin America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 88 Mexico: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 89 Mexico: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 90 Mexico: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 91 Brazil: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 92 Brazil: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 93 Brazil: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 94 Argentina: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 95 Argentina: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 96 Argentina: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 97 Rest of Latin America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • Table 98 Rest of Latin America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • Table 99 Rest of Latin America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • List of Figures:
  • Figure 1. Global Targeted Protein Degradation Market, 2020-2034 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Targeted Protein Degradation Market, by Type, 2024 & 2034 (USD Million)
  • Figure 8. Market by Therapeutic Area
  • Figure 9. Global Targeted Protein Degradation Market, by Therapeutic Area, 2024 & 2034 (USD Million)
  • Figure 10. Market by Route of Administration
  • Figure 11. Global Targeted Protein Degradation Market, by Route of Administration, 2024 & 2034 (USD Million)
目次
Product Code: PM5247

The global targeted protein degradation market size is expected to reach USD 3547.91 million by 2034, according to a new study by Polaris Market Research. The report "Targeted Protein Degradation Market Size, Share, Trends, Industry Analysis Report: By Type, Therapeutic Area (Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, and Others), Route of Administration, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The targeted protein degradation (TPD) market is experiencing significant growth, driven by advances in precision medicine and increased investments in biotechnology. A key driver is the potential of TPD to target previously "undruggable" proteins, opening new therapeutic avenues for complex diseases such as cancer and neurodegenerative disorders.

Opportunities in this market are expected to rise during the forecast period as pharmaceutical companies collaborate with academic institutions and tech firms to develop novel degraders. The emerging trend toward personalized medicine and the growing focus on small-molecule therapeutics also fuel market demand. Overall, with increasing research activities and clinical trials, the TPD market is poised for rapid expansion.

Targeted Protein Degradation Market Report Highlights:

Based on type, the proteolysis-targeting chimeric molecules (PROTACs) segment dominates the market, being widely adopted due to their ability to degrade a broad range of proteins. Degronimids are expected to witness rapid growth, driven by advancements in small-molecule therapeutics.

In terms of therapeutic area, the oncological disorders segment holds the largest share, as cancer treatments heavily rely on targeted protein degradation. The neurological disorders segment is projected to grow rapidly, with increasing research on neurodegenerative diseases such as Alzheimer's.

By route of administration, the intravenous segment dominates the market; the IV route is especially used for therapies requiring direct and controlled delivery.

North America leads the TPD market, owing to strong R&D activities and pharmaceutical investments. Asia Pacific is the fastest-growing region, driven by rising healthcare expenditure, growing biotechnology sectors, and an increasing focus on innovative therapies.

Some of the key players in the market are Arvinas, Kymera Therapeutics, and Nurix Therapeutics.

Polaris Market Research has segmented the targeted protein degradation market report on the basis of type, therapeutic area, route of administration, and region:

By Type Outlook (Revenue - USD Million, 2020-2034)

  • Degronimids
  • Immunomodulatory Drugs (IMiDs)
  • Proteolysis-Targeting Chimeric Molecules (PROTACs)
  • Sudden Acquired Retinal Degeneration Syndrome (SARDs)
  • Selective Estrogen Receptor Degraders (SERDs)
  • Others

By Therapeutic Area Outlook (Revenue - USD Million, 2020-2034)

  • Inflammatory Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Others

By Route of Administration Outlook (Revenue - USD Million, 2020-2034)

  • Oral
  • Intravenous
  • Others

By Regional Outlook (Revenue - USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Targeted Protein Degradation Market Insights

  • 4.1. Targeted Protein Degradation Market - Market Snapshot
  • 4.2. Targeted Protein Degradation Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Expansion in Oncology Applications
      • 4.2.1.2. Rise in Neurological Disorder Treatments
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Complexity of Drug Development and Clinical Validation
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Targeted Protein Degradation Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Targeted Protein Degradation Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
  • 5.3. Degronimids
    • 5.3.1. Global Targeted Protein Degradation Market, by Degronimids, by Region, 2020-2034 (USD Million)
  • 5.4. Immunomodulatory Drugs (IMiDs)
    • 5.4.1. Global Targeted Protein Degradation Market, by Immunomodulatory Drugs (IMiDs), by Region, 2020-2034 (USD Million)
  • 5.5. Proteolysis-Targeting Chimeric Molecules (PROTACs)
    • 5.5.1. Global Targeted Protein Degradation Market, by Proteolysis-Targeting Chimeric Molecules (PROTACs), by Region, 2020-2034 (USD Million)
  • 5.6. Sudden Acquired Retinal Degeneration Syndrome (SARDs)
    • 5.6.1. Global Targeted Protein Degradation Market, by Sudden Acquired Retinal Degeneration Syndrome (SARDs), by Region, 2020-2034 (USD Million)
  • 5.7. Selective Estrogen Receptor Degraders (SERDs)
    • 5.7.1. Global Targeted Protein Degradation Market, by Selective Estrogen Receptor Degraders (SERDs), by Region, 2020-2034 (USD Million)
  • 5.8. Others
    • 5.8.1. Global Targeted Protein Degradation Market, by Others, by Region, 2020-2034 (USD Million)

6. Global Targeted Protein Degradation Market, by Therapeutic Area

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
  • 6.3. Inflammatory Disorders
    • 6.3.1. Global Targeted Protein Degradation Market, by Inflammatory Disorders, by Region, 2020-2034 (USD Million)
  • 6.4. Neurological Disorders
    • 6.4.1. Global Targeted Protein Degradation Market, by Neurological Disorders, by Region, 2020-2034 (USD Million)
  • 6.5. Oncological Disorders
    • 6.5.1. Global Targeted Protein Degradation Market, by Oncological Disorders, by Region, 2020-2034 (USD Million)
  • 6.6. Respiratory Disorders
    • 6.6.1. Global Targeted Protein Degradation Market, by Respiratory Disorders, by Region, 2020-2034 (USD Million)
  • 6.7. Others
    • 6.7.1. Global Targeted Protein Degradation Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Targeted Protein Degradation Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • 7.3. Oral
    • 7.3.1. Global Targeted Protein Degradation Market, by Oral, by Region, 2020-2034 (USD Million)
  • 7.4. Intravenous
    • 7.4.1. Global Targeted Protein Degradation Market, by Intravenous, by Region, 2020-2034 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Targeted Protein Degradation Market, by Others, by Region, 2020-2034 (USD Million)

8. Global Targeted Protein Degradation Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Targeted Protein Degradation Market Assessment, By Geography, 2020-2034 (USD Million)
  • 8.3. Targeted Protein Degradation Market - North America
    • 8.3.1. North America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
    • 8.3.2. North America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
    • 8.3.3. North America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.3.4. Targeted Protein Degradation Market - US
      • 8.3.4.1. US: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.3.4.2. US: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.3.4.3. US: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.3.5. Targeted Protein Degradation Market - Canada
      • 8.3.5.1. Canada: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.3.5.2. Canada: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.3.5.3. Canada: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • 8.4. Targeted Protein Degradation Market - Europe
    • 8.4.1. Europe: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
    • 8.4.2. Europe: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
    • 8.4.3. Europe: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.4.4. Targeted Protein Degradation Market - UK
      • 8.4.4.1. UK: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.4.4.2. UK: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.4.4.3. UK: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.4.5. Targeted Protein Degradation Market - France
      • 8.4.5.1. France: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.4.5.2. France: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.4.5.3. France: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.4.6. Targeted Protein Degradation Market - Germany
      • 8.4.6.1. Germany: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.4.6.2. Germany: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.4.6.3. Germany: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.4.7. Targeted Protein Degradation Market - Italy
      • 8.4.7.1. Italy: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.4.7.2. Italy: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.4.7.3. Italy: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.4.8. Targeted Protein Degradation Market - Spain
      • 8.4.8.1. Spain: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.4.8.2. Spain: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.4.8.3. Spain: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.4.9. Targeted Protein Degradation Market - Netherlands
      • 8.4.9.1. Netherlands: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.4.9.2. Netherlands: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.4.9.3. Netherlands: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.4.10. Targeted Protein Degradation Market - Russia
      • 8.4.10.1. Russia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.4.10.2. Russia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.4.10.3. Russia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.4.11. Targeted Protein Degradation Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.4.11.2. Rest of Europe: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.4.11.3. Rest of Europe: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • 8.5. Targeted Protein Degradation Market - Asia Pacific
    • 8.5.1. Asia Pacific: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
    • 8.5.2. Asia Pacific: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
    • 8.5.3. Asia Pacific: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.5.4. Targeted Protein Degradation Market - China
      • 8.5.4.1. China: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.5.4.2. China: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.5.4.3. China: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.5.5. Targeted Protein Degradation Market - India
      • 8.5.5.1. India: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.5.5.2. India: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.5.5.3. India: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.5.6. Targeted Protein Degradation Market - Malaysia
      • 8.5.6.1. Malaysia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.5.6.2. Malaysia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.5.6.3. Malaysia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.5.7. Targeted Protein Degradation Market - Japan
      • 8.5.7.1. Japan: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.5.7.2. Japan: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.5.7.3. Japan: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.5.8. Targeted Protein Degradation Market - Indonesia
      • 8.5.8.1. Indonesia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.5.8.2. Indonesia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.5.8.3. Indonesia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.5.9. Targeted Protein Degradation Market - South Korea
      • 8.5.9.1. South Korea: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.5.9.2. South Korea: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.5.9.3. South Korea: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.5.10. Targeted Protein Degradation Market - Australia
      • 8.5.10.1. Australia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.5.10.2. Australia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.5.10.3. Australia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.5.11. Targeted Protein Degradation Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.5.11.2. Rest of Asia Pacific: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.5.11.3. Rest of Asia Pacific: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • 8.6. Targeted Protein Degradation Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
    • 8.6.2. Middle East & Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
    • 8.6.3. Middle East & Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.6.4. Targeted Protein Degradation Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.6.4.2. Saudi Arabia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.6.4.3. Saudi Arabia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.6.5. Targeted Protein Degradation Market - UAE
      • 8.6.5.1. UAE: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.6.5.2. UAE: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.6.5.3. UAE: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.6.6. Targeted Protein Degradation Market - Israel
      • 8.6.6.1. Israel: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.6.6.2. Israel: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.6.6.3. Israel: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.6.7. Targeted Protein Degradation Market - South Africa
      • 8.6.7.1. South Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.6.7.2. South Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.6.7.3. South Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.6.8. Targeted Protein Degradation Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.6.8.2. Rest of Middle East & Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.6.8.3. Rest of Middle East & Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
  • 8.7. Targeted Protein Degradation Market - Latin America
    • 8.7.1. Latin America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
    • 8.7.2. Latin America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
    • 8.7.3. Latin America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.7.4. Targeted Protein Degradation Market - Mexico
      • 8.7.4.1. Mexico: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.7.4.2. Mexico: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.7.4.3. Mexico: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.7.5. Targeted Protein Degradation Market - Brazil
      • 8.7.5.1. Brazil: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.7.5.2. Brazil: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.7.5.3. Brazil: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.7.6. Targeted Protein Degradation Market - Argentina
      • 8.7.6.1. Argentina: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.7.6.2. Argentina: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.7.6.3. Argentina: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
    • 8.7.7. Targeted Protein Degradation Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
      • 8.7.7.2. Rest of Latin America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
      • 8.7.7.3. Rest of Latin America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Arvinas
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Kymera Therapeutics
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Nurix Therapeutics
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. C4 Therapeutics
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Foghorn Therapeutics
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Zymeworks
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Bristol-Myers Squibb
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. AbbVie
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Molteni Farmaceutici
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development